{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2261846"],"location":["China"],"study_start_month":["1"],"keyword":["Irinotecan","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Withdrawn"],"additional_accession":[]},"is_claimable":false,"name":"Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer","description":"Phase I Study of biweekly combination therapy with S-1, Irinotecan, and Bevacizumab as 1-line Chemotherapy in Patients With Advanced Colorectal Cancer.","dates":{"creation":"2018-01-15"},"accession":"2261846","cross_references":{"ClinicalTrials___gov":["NCT03380689"]}}